76% of UK pharmacies brace for Wegovy pill surge as oral GLP-1 launches

For healthcare providers and pharmacy operators, the oral Wegovy launch isn't just a new product—it's a system stress test. With 76% of community pharmacies anticipating a substantial new patient caseload, the pressure is on to manage consultations, ensure safe dispensing, and combat a looming counterfeit drug wave. This is the frontline reality of turning a clinical breakthrough into safe, scalable population health impact.

The United Kingdom has reached a watershed moment in obesity treatment with the launch of the world's first GLP-1 receptor agonist pill for weight loss. Novo Nordisk's Wegovy (semaglutide) oral tablet became available in UK pharmacies on Monday, 6 July 2026, following approval by the Medicines and Healthcare products Regulatory Agency (MHRA) in June. This marks a significant expansion from the injectable form of semaglutide, addressing a crucial unmet need for patients who cannot or will not use injectables. The oral formulation uses a proprietary absorption enhancer (SNAC) to enable systemic delivery of the peptide, overcoming the historic challenge of oral peptide bioavailability.

“

Novo Nordisk's Wegovy (semaglutide) oral tablet became available in UK pharmacies on Monday, 6 July 2026, following approval by the Medicines and Healthcare products Regulatory Agency (MHRA) in June.

The UK launch begins with the two lowest dose strengths—1.5 mg and 4 mg—dispensed through licensed weight management programmes in community pharmacies. The full titration schedule escalates to 9 mg and 25 mg, with each dose step requiring at least one month to mitigate gastrointestinal side effects. The NPA survey, conducted among 310 pharmacies, reveals that 76% anticipate initiating a significant number of new eligible patients on the pill in the coming months, underscoring the vast pent-up demand. Already, 49% of pharmacies reported a surge in patient inquiries since the MHRA approval, indicating that awareness is high and stigma around injectable therapies may have suppressed prior uptake.

However, the launch is not without significant operational and safety concerns. A striking 97% of surveyed pharmacists expressed anxiety that the pill format could fuel a counterfeit drug crisis. Historically, oral medications are easier to replicate than injectable pens, and the black market for weight loss drugs has grown alongside GLP-1 therapies. The NPA, through chairman Olivier Picard, issued a stark warning that patients must obtain the drug only from regulated pharmacies following thorough consultation. This vigilance is critical because falsified semaglutide pills could contain incorrect doses, harmful contaminants, or no active ingredient, posing serious health risks.